Alpha Tau Medical Ltd. DRTS
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.53
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $32.1M | $27.0M | $26.4M | $20.9M | $11.4M | $7.5M | $6.6M | — |
| SG&A | $8.4M | $6.7M | $7.3M | $10.3M | $1.9M | $1.4M | $977.0K | — |
| Operating income | -$42.3M | -$36.0M | -$35.7M | -$32.1M | -$13.8M | -$9.2M | $8.0M | — |
| Interest expense | $347.0K | $303.0K | $75.0K | — | — | — | — | — |
| Pre-tax income | -$42.5M | -$31.7M | -$29.1M | -$33.7M | -$27.3M | -$8.7M | $8.3M | — |
| Income tax | $121.0K | $6.0K | $16.0K | $20.0K | $7.0K | $158.0K | $146.0K | — |
| Net income | -$42.6M | -$31.8M | -$29.2M | -$33.8M | -$27.3M | -$8.9M | -$8.4M | — |
| EPS, basic | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 | -0.22 | -0.25 | — |
| EPS, diluted | -0.53 | -0.45 | -0.42 | -0.53 | -0.67 | -0.22 | -0.25 | — |
| Shares, diluted (wtd. avg.) | 80.6M | 69.9M | 69.4M | 63.5M | 40.5M | 40.3M | 33.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.2M | $13.7M | $12.7M | $6.7M | $23.9M | $16.2M | $1.8M | $13.6M |
| Short-term investments | $60.9M | $45.9M | $69.1M | $98.7M | $8.1M | — | — | — |
| Total current assets | $78.3M | $64.2M | $85.8M | $106.5M | $32.6M | $47.5M | — | — |
| Property, plant and equipment | $19.7M | $13.9M | $12.8M | $7.5M | $7.5M | $5.4M | — | — |
| Total assets | $105.7M | $86.2M | $107.4M | $120.1M | $42.2M | $53.0M | — | — |
| Accounts payable | — | — | $2.6M | $1.4M | $1.2M | $964.0K | — | — |
| Total current liabilities | $10.5M | $8.7M | $7.1M | $4.3M | $4.4M | $2.1M | — | — |
| Long-term debt | — | — | $5.2M | — | — | — | — | — |
| Total liabilities | $28.6M | $23.5M | $22.9M | $14.5M | $23.0M | $7.5M | — | — |
| Retained earnings | -$190.1M | -$147.5M | -$115.8M | -$86.6M | -$52.8M | -$25.6M | — | — |
| Total equity | $77.1M | $62.7M | $84.5M | $105.7M | -$34.8M | -$8.4M | -$193.0K | $1.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.7M | -$19.8M | -$18.0M | -$23.9M | -$11.8M | -$7.3M | -$6.9M | — |
| Depreciation and amortisation | $1.2M | $1.1M | $1.1M | $979.0K | $776.0K | $86.0K | $66.0K | — |
| Stock-based compensation | $10.6M | $9.9M | $7.9M | $6.7M | $812.0K | $596.0K | $546.0K | — |
| Capital expenditure | $6.1M | $2.2M | $6.4M | $904.0K | $2.9M | $3.8M | $1.3M | — |
| Investing cash flow | -$20.6M | $20.8M | $18.7M | -$89.9M | $19.3M | -$7.8M | -$10.2M | — |
| Financing cash flow | $45.8M | $25.0K | $5.3M | $96.9M | $111.0K | $29.3M | $5.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-025174.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Buybacks
- Receivables
- Stock-based compensation
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Buybacks | — | — | — | — | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | — |
| Stock-based compensation | — | $546.0K | $596.0K | $812.0K | $6.7M | $7.9M | $9.9M | $10.6M |
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |